Research Article

Evaluation of outcomes of 8-week therapy with ledipasvir/sofosbuvir or glecaprevir/pibrentasvir in veterans with hepatitis C infection

L Anri Lemoine and Marisel Segarra-Newnham*

Published: 13 November, 2019 | Volume 3 - Issue 1 | Pages: 027-030

Hepatitis C Virus (HCV) infection is usually treated with direct acting antivirals (DAAs) for 12 weeks. In treatment naive patients with genotype (GT) 1 infection without cirrhosis and baseline viral load < 6 million, 8 weeks of Ledipasvir/Sofosbuvir (LDV/SOF) is an option. Eight weeks with Glecaprevir/Pibrentasvir (GLE/PIB) is an option for patients with GT 1 through 6 without cirrhosis. Our objective was to evaluate achievement of Sustained Virologic Response (SVR) after 8 weeks of LDV/SOF or GLE/PIB in our HCV-infected veterans. Patients with HCV infection that received GLE/PIB or LDV/SOF for a planned 8 weeks of therapy in the past four years were reviewed (January 2015-September 2018). Treatment outcomes were evaluated through medical record review.

Two hundred sixty-five veterans were initiated on 8 weeks of therapy with either GLE/PIB or LDV/SOF. Of these, 231 (87%) were initiated on 8 weeks of LDV/SOF and 34 (13%) were initiated on 8 weeks of GLE/PIB. The majority of patients had GT 1 (93%) infection. One hundred and ninety-five veterans who completed 8 weeks of LDV/SOF and 30 veterans on GLE/PIB had follow-up viral loads. The overall SVR was 95%. Treatment with GLE/PIB resulted in a higher SVR rate (100%) compared to LDV/SOF (95%). Elderly patients had similar SVR rates. Treatment with 8 weeks of DAA is effective in our veteran population and showed an SVR rate similar to literature reports. The SVR for patients treated with 8 weeks LDV/SOF was slightly lower than the SVR for GLE/PIB; however, the GLE/PIB population was smaller

Read Full Article HTML DOI: 10.29328/journal.acgh.1001011 Cite this Article Read Full Article PDF


  1. Centers for Disease Control and Prevention. Viral Hepatitis: Hepatitis C Information. 2019.
  2. Messina JP, Humphreys I, Flaxman A, Brown A, Cooke GS, et al. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology. 2014; 61: 77-87. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/25069599
  3. Abutaleb A, Kottilil S, Wilson E. Glecaprevir/pibrentasvir expands reach while reducing cost and duration of hepatitis C virus therapy. Hepatol Int. 2018; 12: 214-222. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/29845496
  4. American Association for the Study of Liver Diseases, and Infectious Diseases Society of America. HCV guidance: recommendations for testing, managing, and treating hepatitis C. 2019
  5. Andres J, Lott S, Qureshi K. Eight-Week Outcomes of Ledipasvir/Sofosbuvir in Noncirrhotic Treatment-Naive Patients with Hepatitis C: Analysis of Pharmacy-Based Data. J Manag Care Spec Pharm. 2018; 24: 23-28. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/29290174
  6. Babatin MA, AlGhamdi AS, Assiri AM, AlBiladi H, AlOthmani HS, et al. Treatment efficacy of ledipasvir/sofosbuvir for 8 weeks in non-cirrhotic chronic hepatitis C genotype 4 patients. Saudi J Gastroenterol. 2019; 25: 55-60. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/30117490
  7. Shiha G, Esmat G, Hassany M, Soliman R, Elbasiony M, et al. Ledipasvir/sofosbuvir with or without ribavirin for 8 or 12 weeks for the treatment of HCV genotype 4 infection: Results from a randomised phase III study in Egypt. Gut. 2019; 68: 721-728. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/29666174
  8. Kowdley KV, Gordon SC, Reddy KR, Rossaro L, Bernstein DE, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med. 2014; 370: 1879-1888. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/24720702
  9. Wyles D, Poordad F, Wang S, Alric L, Felizarta F, et al. (2018) Glecaprevir/pibrentasvir for hepatitis C virus genotype 3 patients with cirrhosis and/or prior treatment experience: A partially randomized phase 3 clinical trial. Hepatology. 2018; 67: 514-523. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/28926120
  10. Rockstroh JK, Lacombe K, Viani RM, Orkin C, Wyles D, et al. Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients Coinfected With Hepatitis C Virus and Human Immunodeficiency Virus Type 1: The EXPEDITION-2 Study. Clin Infect Dis. 2018; 67: 1010-1017. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/29566246
  11. Gane E, Poordad F, Zadeikis N, Valdes J, Lin CW, et al. Safety and Pharmacokinetics of Glecaprevir/Pibrentasvir in Adults with Chronic Genotype 1-6 Hepatitis C Virus Infections and Compensated Liver Disease. Clin Infect Dis. 2019; 69: 1657-1664. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/30923816
  12. Tavabie OD. Should we screen for cirrhosis? BMJ. 2017; 358: j3233.
  13. Foster GR, Asselah T, Kopecky-Bromberg S, Lei Y, et al. Safety and efficacy of glecaprevir/pibrentasvir for the treatment of chronic hepatitis C in patients aged 65 years or older. PLoS One. 2019; 14: e0208506. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/30601818


Figure 1

Figure 1

Similar Articles

Recently Viewed

Read More

Most Viewed

Read More

Help ?